Vir is holding off on advancing the combination therapy to Phase III trials until it secures a development partner.

Analysts estimate that Vir Biotechnology will report an earnings per share (EPS) of $-0.84. Vir Biotechnology bulls will hope to hear the company announce they've not only beaten that estimate, but ...

Net Cash Consumed: $75.6 million in Q1 2025. Vir Biotechnology Inc (NASDAQ:VIR) successfully initiated the ECLIPSE Phase III registrational program for hepatitis delta virus, marking a significant ...

Vir Biotechnology has demonstrated consistent progress in its clinical programs, particularly with the initiation of the ECLIPSE Phase III trials for hepatitis delta virus. The company’s ...

Ph.D., MBA, Chief Executive Officer, Vir Biotechnology. "We successfully dosed the first patient in our ECLIPSE Phase 3 registrational program for hepatitis delta, a devastating disease with no ...

Vir Biotechnology (NASDAQ:VIR) is set to give its latest quarterly earnings report on Wednesday, 2025-05-07. Here's what investors need to know before the announcement. Analysts estimate that Vir ...